🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory Acute Myeloid Leukemia

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332Phase 12 sites📍 Edegem📍 Roeselare University Hospital, Antwerp · Tests: Venetoclax, 6-mercaptopurine Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML NCT05024552Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Gilteritinib, Vyxeos CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD117 CAR T-cells Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) NCT05580601Phase 1, Phase 21 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati · Tests: CIML-NK Cells A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites📍 Beijing📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG-115, Azacitidine, Cytarabine A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05924750Phase 18 sites📍 Hefei📍 Beijing📍 Haerbin Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M11D1 Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax NCT07471841Phase 21 site📍 Winston-Salem Timothy Pardee · Tests: Olutasidenib, Azacitidine (AZA) Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247EARLY Phase 11 site📍 Beijing Peking University People's Hospital · Tests: JD123 injection Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752Phase 1, Phase 23 sites📍 Charlotte📍 Winston-Salem📍 Houston ARCE Therapeutics, Inc. · Tests: ARD103, Cyclophosphamide, Fludarabine Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML NCT05305859Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: venetoclax combining chidamide and azacitidine (VCA) Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML NCT06156579Phase 21 site📍 Tübingen University Hospital Tuebingen · Tests: Decitabine, Venetoclax Individualized AML Treatment NCT07613385n/a1 site📍 Duarte City of Hope Medical Center · Tests: Observational PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML NCT05105152Phase 11 site📍 Seattle Seattle Children's Hospital · Tests: SC-DARIC33 Novel Digital Application for Patients With Acute Leukemia NCT06472128NA3 sites📍 Boston📍 Durham📍 Seattle Massachusetts General Hospital · Tests: DREAMLAND, VITAL WELLNESS A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06763341Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, PCNA Inhibitor AOH1996, Venetoclax IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. NCT06713837Phase 347 sites📍 Brno📍 Hradec Králové📍 Olomouc Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: High intensity therapies, Low intensity therapies Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome NCT07582172Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT04774393Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine and Cedazuridine, Enasidenib, Ivosidenib, Venetoclax HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML NCT06594445Phase 11 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: GTB-360 Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia NCT06265545NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Ivosidenib, Venetoclax, Gilteritinib, Homoharringtonine, Cytarabine HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT06084819Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, Best-Available Therapy… A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) NCT03113643Phase 13 sites📍 Duarte📍 Boston📍 Houston Dana-Farber Cancer Institute · Tests: Azacitidine, SL-401, Venetoclax Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML NCT05503134Phase 1, Phase 21 site📍 Columbus Nationwide Children's Hospital · Tests: Universal Donor Natural Killer Cells
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy